Grifols, S.A. (GIKLY)
USD 4.8
(13.48%)
USD 4.8
(13.48%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 3.45 Billion EUR | 8.06% |
| 2022 | 3.2 Billion EUR | 41.69% |
| 2021 | 2.25 Billion EUR | 12.84% |
| 2020 | 2 Billion EUR | -14.53% |
| 2019 | 2.34 Billion EUR | 20.17% |
| 2018 | 1.94 Billion EUR | 19.64% |
| 2017 | 1.62 Billion EUR | -0.83% |
| 2016 | 1.64 Billion EUR | 14.78% |
| 2015 | 1.43 Billion EUR | 19.88% |
| 2014 | 1.19 Billion EUR | 26.1% |
| 2013 | 946.91 Million EUR | -5.18% |
| 2012 | 998.64 Million EUR | -3.08% |
| 2011 | 1.03 Billion EUR | 95.19% |
| 2010 | 527.86 Million EUR | 8.96% |
| 2009 | 484.46 Million EUR | 29.85% |
| 2008 | 373.09 Million EUR | 37.85% |
| 2007 | 270.65 Million EUR | 14.94% |
| 2006 | 235.47 Million EUR | -5.64% |
| 2005 | 249.54 Million EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 3.64 Billion EUR | 5.44% |
| 2024 Q2 | 3.62 Billion EUR | -0.66% |
| 2023 Q4 | 3.45 Billion EUR | -0.79% |
| 2023 Q3 | 3.48 Billion EUR | 5.1% |
| 2023 Q1 | 3.27 Billion USD | 2.36% |
| 2023 Q2 | 3.31 Billion EUR | 1.23% |
| 2023 FY | 3.45 Billion EUR | 8.06% |
| 2022 Q4 | 3.2 Billion USD | 0.0% |
| 2022 FY | 3.2 Billion EUR | 41.69% |
| 2022 Q2 | 2.93 Billion EUR | 0.0% |
| 2022 Q3 | 3.2 Billion EUR | 9.13% |
| 2022 Q1 | - EUR | -100.0% |
| 2021 Q1 | 2.13 Billion EUR | 6.78% |
| 2021 Q2 | 2.12 Billion EUR | -0.64% |
| 2021 Q3 | 2.25 Billion EUR | 6.35% |
| 2021 FY | 2.25 Billion EUR | 12.84% |
| 2021 Q4 | 2.25 Billion USD | 0.0% |
| 2020 FY | 2 Billion EUR | -14.53% |
| 2020 Q4 | 2 Billion EUR | 0.82% |
| 2020 Q3 | 1.98 Billion EUR | -4.75% |
| 2020 Q2 | 2.08 Billion EUR | -15.22% |
| 2020 Q1 | 2.45 Billion EUR | 4.99% |
| 2019 Q4 | 2.34 Billion EUR | 0.66% |
| 2019 FY | 2.34 Billion EUR | 20.17% |
| 2019 Q1 | 2.11 Billion EUR | 8.53% |
| 2019 Q2 | 2.2 Billion EUR | 4.26% |
| 2019 Q3 | 2.32 Billion EUR | 5.5% |
| 2018 Q1 | 1.67 Billion EUR | 2.75% |
| 2018 FY | 1.94 Billion EUR | 19.64% |
| 2018 Q4 | 1.94 Billion EUR | 4.57% |
| 2018 Q3 | 1.86 Billion EUR | 3.18% |
| 2018 Q2 | 1.8 Billion EUR | 7.92% |
| 2017 Q4 | 1.62 Billion EUR | 2.2% |
| 2017 Q2 | 1.59 Billion EUR | -5.33% |
| 2017 FY | 1.62 Billion EUR | -0.83% |
| 2017 Q1 | 1.68 Billion EUR | 2.6% |
| 2017 Q3 | 1.59 Billion EUR | -0.1% |
| 2016 Q4 | 1.64 Billion EUR | 6.37% |
| 2016 Q2 | 1.53 Billion EUR | 5.85% |
| 2016 FY | 1.64 Billion EUR | 14.78% |
| 2016 Q1 | 1.44 Billion EUR | 1.04% |
| 2016 Q3 | 1.54 Billion EUR | 0.89% |
| 2015 FY | 1.43 Billion EUR | 19.88% |
| 2015 Q4 | 1.43 Billion EUR | 5.29% |
| 2015 Q3 | 1.35 Billion EUR | 1.25% |
| 2015 Q2 | 1.34 Billion EUR | -2.08% |
| 2015 Q1 | 1.37 Billion EUR | 14.84% |
| 2014 Q3 | 1.14 Billion EUR | 10.91% |
| 2014 Q2 | 1.03 Billion EUR | 0.96% |
| 2014 FY | 1.19 Billion EUR | 26.1% |
| 2014 Q1 | 1.02 Billion EUR | 7.89% |
| 2014 Q4 | 1.19 Billion EUR | 4.38% |
| 2013 Q1 | 1 Billion EUR | 0.36% |
| 2013 Q2 | 990.23 Million EUR | -1.2% |
| 2013 FY | 946.91 Million EUR | -5.18% |
| 2013 Q3 | 985.27 Million EUR | -0.5% |
| 2013 Q4 | 946.91 Million EUR | -3.89% |
| 2012 Q1 | 996.17 Million EUR | -3.32% |
| 2012 Q4 | 998.64 Million EUR | -2.55% |
| 2012 Q3 | 1.02 Billion EUR | -0.79% |
| 2012 FY | 998.64 Million EUR | -3.08% |
| 2012 Q2 | 1.03 Billion EUR | 3.69% |
| 2011 Q4 | 1.03 Billion EUR | 3.34% |
| 2011 Q2 | 997.82 Million EUR | 0.0% |
| 2011 FY | 1.03 Billion EUR | 95.19% |
| 2011 Q3 | 997.02 Million EUR | -0.08% |
| 2010 Q4 | 527.86 Million EUR | 0.0% |
| 2010 FY | 527.86 Million EUR | 8.96% |
| 2009 FY | 484.46 Million EUR | 29.85% |
| 2008 FY | 373.09 Million EUR | 37.85% |
| 2007 FY | 270.65 Million EUR | 14.94% |
| 2006 FY | 235.47 Million EUR | -5.64% |
| 2005 FY | 249.54 Million EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AstraZeneca PLC | 5.41 Billion USD | 36.133% |
| Bristol-Myers Squibb Company PFD CONV 2 | 2.66 Billion USD | -29.95% |
| CSPC Pharmaceutical Group Limited | 442.43 Million USD | -681.879% |
| Clarus Therapeutics Holdings, Inc. | 14.21 Million USD | -24237.111% |
| Novartis AG | 5.91 Billion USD | 41.497% |
| PT Kalbe Farma Tbk. | 451.27 Million USD | -666.548% |